Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas
Endocrine Oncology · 01.01.2025 · 5 (1)
DOI: 10.1530/eo-24-0083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Oncology, online erschienen am 07.08.2025. Verfasst von Eleni Armeni und 11 weiteren Autor:innen. Beteiligte Einrichtung: Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital NHS Trust, London, United Kingdom. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Glucagonomas are rare islet cell tumours, accounting for 2% of such tumours, with an annual incidence of 0.01–0.1 per million. This study aimed to describe diagnostic characteristics and treatment outcomes in patients with glucagonoma from a major referral centre.
Design
A retrospective case series included patients diagnosed with glucagonoma at the ENETS Centre of Excellence, Royal Free Hospital, London, UK.
Methods
Electronic patient records were reviewed to document baseline disease characteristics and treatment outcomes. Disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) were calculated using the Kaplan–Meier method.
Results
Twenty patients (75% male, age 56.6 ± 11.6 years, mean Ki-67 index 7.3 ± 7, mean ± SD) were included; 50% had liver metastases at diagnosis. The median OS was 34 months (95% CI: 30.3–37.7). Median OS was 34, 9, and 71 months for patients with liver, lung, and skeletal metastases, respectively. At diagnosis, migratory necrolytic erythema was linked to poorer OS (22 months, 95% CI: 14.3–29.7). Median DFS following surgery was 25 months (95% CI: 3.5–46.5). For inoperable disease, Lutetium-177 (177Lu)-DOTATATE peptide receptor radionuclide therapy (PRRT) demonstrated efficacy in disease control. Other treatments included somatostatin analogues, chemotherapy, and molecular-targeted agents.
Conclusion
Tumour grade, metastases, and NME at diagnosis influence OS in glucagonoma. Surgery is associated with the best PFS as first-line therapy, while 177Lu-DOTATATE PRRT effectively controls disease progression. Further studies are needed to optimise treatment sequencing for advanced glucagonoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital NHS Trust, London, United Kingdom.
- Endocrine Unit, 2nd Propaedeutic Department of Internal Medicine, Research Institute & Diabetes Center, Medical School, University of Athens, Attikon University Hospital, Athens, Greece.
- Nuclear Medicine Department, Royal Free Hospital NHS Trust, London, United Kingdom.
ORCID-Profile: Eleni Armeni, Shaunak Navalkissoor, Ashley B Grossman
Zitieren
APA
Armeni, E., Branton, A., Porto, J., Mandair, D., Hayes, A. R., Manta, A., Navalkissoor, S., Gnanasegaran, G., Quigley, A. M., Grossman, A. B., Caplin, M., & Toumpanakis, C. (2025). Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas. Endocrine Oncology, 5(1). https://doi.org/10.1530/eo-24-0083
Vancouver
Armeni E, Branton A, Porto J, Mandair D, Hayes AR, Manta A, et al. Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas. Endocrine Oncology. 2025;5(1). doi:10.1530/eo-24-0083
BibTeX
@article{Armeni2025,
author = {Armeni, Eleni and Branton, Alexander and Porto, Juliana and Mandair, Dalvinder and Hayes, Aimee R and Manta, Aspasia and Navalkissoor, Shaunak and Gnanasegaran, Gopinath and Quigley, Ann-Marie and Grossman, Ashley B and Caplin, Martyn and Toumpanakis, Christos},
title = {Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas},
journal = {Endocrine Oncology},
year = {2025},
volume = {5},
number = {1},
doi = {10.1530/eo-24-0083}
}
EUVIMED